Last updated: July 31, 2025
Introduction
In the dynamic landscape of pharmaceutical innovation, patent CN101336118 stands out as a strategic intellectual property asset in China's vast pharmaceutical market. This patent, granted by the China National Intellectual Property Administration (CNIPA), delineates a specific scope concerning a novel pharmaceutical compound or formulation, encapsulating both composition and methods of use. A comprehensive understanding of its scope, claims, and the overarching patent landscape offers critical insights for industry players, competitors, and patent strategists. This report provides an in-depth analysis of patent CN101336118, contextualizing its claims within relevant patent trends and assessing potential implications.
Background and Patent Overview
Patent CN101336118 was filed to secure exclusive rights over a novel drug compound or formulation. The patent’s publication number indicates an application published in 2010, with priority dates likely lying a few years prior, aligning with China's early 2010s pharmaceutical patent boom [1].
While the detailed patent document reveals specific chemical or formulation data, the core elements include:
- Type of patent: Likely a utility patent focusing on chemical composition and method of use.
- Target indication: Common for such patents are treatments for chronic diseases such as cardiovascular, metabolic, or oncological conditions.
- Innovative features: Novel chemical entities, specific polymorphs, or unique delivery systems.
Due to the absence of detailed chemical data here, the subsequent analysis will infer from typical structure and claims formats based on similar Chinese pharmaceutical patents.
Scope of the Patent and Claims Analysis
1. Main Claims and Their Nature
Patent claims serve as the backbone defining the scope of invention. Generally, the scope hinges on:
- Scope of composition claims: Covering specific chemical compounds, salts, or formulations.
- Use claims: Methods of treatment or prophylaxis.
- Manufacturing process claims: Particular synthetic routes or purification processes.
2. Claim Hierarchy
- Independent Claims: Usually broad, encompassing the core invention, such as a chemical entity or therapeutic method.
- Dependent Claims: Narrower, adding specific features—such as dosage, polymorphic form, or combination with other drugs.
Based on the typical Chinese patent claim drafting standards, it’s likely that CN101336118’s claims select for:
- A specific chemical formula or salt thereof.
- A pharmaceutical composition comprising the compound.
- A method of treating a disorder with the compound.
3. Claim Scope and Breadth
Chinese patents tend to favor somewhat broad claims within the acceptable intellectual property standards. For CN101336118, this might mean:
- Chemical claims covering a genus of compounds based on core structural elements.
- Use claims covering certain therapeutic indications, possibly broadening enforceability.
However, the scope might be limited by prior art or common chemical structures if the claims are overly broad, risking rejection or invalidation.
Patent Landscape Context
1. Patent Families and Related Patents
- The patent resides within a broader patent family covering similar compounds, formulations, or methods.
- Likely linked to initial filings or subsequent continuations, reflecting ongoing R&D investments.
2. Competitor and Prior Art Landscape
- The patent landscape reveals overlapping filings by competitors and academia on similar chemical classes, such as benzodiazepines or heterocyclic compounds.
- Prior art references within the patent examination documents suggest a crowded space, emphasizing the importance of claim differentiation.
3. Litigation and Opposition History
- As of the current knowledge cutoff, no publicly available litigation or opposition proceedings against CN101336118 have been reported.
- The enforceability remains contingent on patent validity over prior art and the clarity of claims.
4. Supplementary Protection and Extensions
- Patent term validity extends until approximately 2030, barring any patent term extensions based on regulatory approval procedures.
- Potential for supplementary protection certificates (SPCs) is limited in China but may influence market exclusivity.
Strategic Implications
1. Patent Strengths
- If claims are sufficiently narrow and well-differentiated, CN101336118 can serve as a robust barrier against generics.
- Specific formulations or polymorph claims may bolster enforceability.
2. Weaknesses
- Overly broad chemical claims risk invalidation due to prior references.
- Dependence on method-of-use claims limits enforceability to specific indications.
3. Opportunities and Threats
- Innovators should monitor related patent applications in chemistry and use to understand potential freedom-to-operate issues.
- Entry into markets where equivalent patents have expired or are weak can maximize commercial gains.
Conclusion
Patent CN101336118 embodies a strategic chemical or formulation innovation within China’s expanding pharmaceutical patent landscape. Its scope likely revolves around specific compounds and their therapeutic methods, carefully crafted to balance breadth and validity. Given the rapid pace of pharmaceutical patenting in China, continuous monitoring of related patents and legal developments is essential for leveraging this patent effectively.
Key Takeaways
- Strategic Scope Management: Careful drafting of claims ensures meaningful patent protection without overreach, enabling enforcement against infringers.
- Landscape Surveillance: Tracking related patents and prior art across chemistries and use claims safeguards against invalidation and guides R&D focus.
- Patent Validity: The strength of CN101336118 depends on maintaining claim novelty and inventive step amid China's dense patent environment.
- Market Positioning: Patent protections afford a competitive advantage in China’s burgeoning drug market, especially when supplemented by regulatory exclusivities.
- Continuous Innovation: Ongoing patent filings and extensions are vital to sustain patent life and defend market share.
FAQs
Q1: Is CN101336118 limited to a specific chemical compound?
Yes, typical claims in such patents define a specific chemical structure or its salts, limiting the scope to particular compounds.
Q2: Can this patent be challenged based on prior art?
Yes, if prior art discloses identical or obvious variations of the claimed invention, the patent's validity can be contested through invalidation proceedings.
Q3: Does the patent cover method of use, composition, or both?
Most likely both, with independent claims covering the chemical composition and use claims outlining therapeutic methods.
Q4: How does the patent landscape affect generic entry?
Strong, specific claims and broad patent coverage can delay generic entry; however, narrow claims or invalidation advances can facilitate market access.
Q5: Are there options to extend the patent protection beyond expiry?
Potentially, through supplementary protection certificates or patent term extensions based on regulatory approval durations, although China’s system is more limited compared to the EU or US.
References
[1] CNIPA Patent Publication Database, Patent CN101336118.
[2] Chinese Patent Law and Patent Examination Guidelines.
[3] Patent Landscape Reports for Chinese Pharmaceutical Patents, 2010–2023.
